Equities

Amoeba SA

Amoeba SA

Actions
Basic MaterialsChemicals
  • Price (EUR)0.498
  • Today's Change-0.002 / -0.40%
  • Shares traded65.37k
  • 1 Year change-15.74%
  • Beta-0.1548
Data delayed at least 15 minutes, as of May 15 2024 16:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-14.30m
  • Incorporated2010
  • Employees25.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Metabolic Explorer SA166.46m-49.34m6.18m425.00--0.065--0.0371-0.9537-0.95373.231.870.6342.355.14349,705.90-18.790.8833-27.121.25-4.97---29.641.321.31-11.390.52660.0033.54123.77-161.53--88.72--
Encres Dubuit SA21.68m-1.32m8.86m178.00--0.40149.760.4085-0.4187-0.41876.907.030.75552.334.38121,814.60-4.591.22-5.381.4337.8240.99-6.071.602.65-18.270.068154.039.860.3702-118.90--13.28--
Amoeba SA0.00-14.30m24.83m25.00---------0.2902-0.29020.00-0.07990.001.24--0.00-152.99-71.18-355.19-149.43---1,422.75---37,185.670.374-54.095.03-------78.22--100.57--
Haffner Energy SA-40.00k-14.52m29.05m78.00--0.8628-----0.3241-0.3241-0.00090.7534-0.0007-----800.00-25.36---30.93----------2.32--0.1363---21.09---242.44------
Orapi SA229.10m-18.68m41.85m916.00--1.00108.700.1827-2.87-2.8935.176.301.224.686.10250,108.10-9.76-1.07-18.10-2.0630.7633.70-8.01-0.88650.709-0.02750.6446--0.8896-2.19-2,655.95---3.85--
Baikowski SA35.95m938.00k50.40m155.0054.891.2011.101.400.24960.24969.7911.410.53860.89036.02231,948.401.415.541.817.0464.0944.272.618.660.9601--0.27229.28-32.13-3.17-85.66-26.806.07--
Florentaise SA58.23m-207.00k54.94m277.00--1.809.150.9435-0.0161-0.01617.323.700.60642.0322.10218,891.00-0.2156---0.3484--41.22---0.3555--0.5228-1.120.5928---13.68---80.10------
Data as of May 15 2024. Currency figures normalised to Amoeba SA's reporting currency: Euro EUR

Institutional shareholders

0.18%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Feb 202470.41k0.14%
Friedland Gestion SASas of 26 Jan 202417.00k0.03%
Iris Finance SAas of 31 Dec 20180.000.00%
Data from 31 Dec 2018 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.